Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1981 Aug;46(2):173–178. doi: 10.1136/hrt.46.2.173

Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment.

W J McKenna, L Harris, G Perez, D M Krikler, C Oakley, J F Goodwin
PMCID: PMC482624  PMID: 7196769

Full text

PDF
173

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRAUNWALD E., LAMBREW C. T., ROCKOFF S. D., ROSS J., Jr, MORROW A. G. IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS. I. A DESCRIPTION OF THE DISEASE BASED UPON AN ANALYSIS OF 64 PATIENTS. Circulation. 1964 Nov;30:SUPPL 4–119. doi: 10.1161/01.cir.29.5s4.iv-3. [DOI] [PubMed] [Google Scholar]
  2. Bruce R. A. Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation. Ann Clin Res. 1971 Dec;3(6):323–332. [PubMed] [Google Scholar]
  3. Doi Y. L., McKenna W. J., Chetty S., Oakley C. M., Goodwin J. F. Prediction of mortality and serious ventricular arrhythmia in hypertrophic cardiomyopathy. An echocardiographic study. Br Heart J. 1980 Aug;44(2):150–157. doi: 10.1136/hrt.44.2.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Doi Y. L., McKenna W. J., Gehrke J., Oakley C. M., Goodwin J. F. M mode echocardiography in hypertrophic cardiomyopathy: diagnostic criteria and prediction of obstruction. Am J Cardiol. 1980 Jan;45(1):6–14. doi: 10.1016/0002-9149(80)90213-1. [DOI] [PubMed] [Google Scholar]
  5. Hardarson T., De la Calzada C. S., Curiel R., Goodwin J. F. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet. 1973 Dec 29;2(7844):1462–1467. doi: 10.1016/s0140-6736(73)92730-x. [DOI] [PubMed] [Google Scholar]
  6. Kaltenbach M., Hopf R., Kober G., Bussmann W. D., Keller M., Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979 Jul;42(1):35–42. doi: 10.1136/hrt.42.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Maron B. J., Lipson L. C., Roberts W. C., Savage D. D., Epstein S. E. "Malignant" hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am J Cardiol. 1978 Jun;41(7):1133–1140. doi: 10.1016/0002-9149(78)90870-6. [DOI] [PubMed] [Google Scholar]
  8. Maron B. J., Roberts W. C., Edwards J. E., McAllister H. A., Jr, Foley D. D., Epstein S. E. Sudden death in patients with hypertrophic cardiomyopathy: characterization of 26 patients with functional limitation. Am J Cardiol. 1978 May 1;41(5):803–810. doi: 10.1016/0002-9149(78)90717-8. [DOI] [PubMed] [Google Scholar]
  9. McKenna W. J., Chetty S., Oakley C. M., Goodwin J. F. Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol. 1980 Jan;45(1):1–5. doi: 10.1016/0002-9149(80)90212-x. [DOI] [PubMed] [Google Scholar]
  10. McKenna W., Deanfield J., Faruqui A., England D., Oakley C., Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol. 1981 Mar;47(3):532–538. doi: 10.1016/0002-9149(81)90535-x. [DOI] [PubMed] [Google Scholar]
  11. Olsson S. B., Brorson L., Varnauskas E. Class 3 antiarrhythmic action in man. Observations from monophasic action potential recordings and amiodarone treatment. Br Heart J. 1973 Dec;35(12):1255–1259. doi: 10.1136/hrt.35.12.1255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rosing D. R., Kent K. M., Maron B. J., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation. 1979 Dec;60(6):1208–1213. doi: 10.1161/01.cir.60.6.1208. [DOI] [PubMed] [Google Scholar]
  13. Rowland E., Krikler D. M. Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. Br Heart J. 1980 Jul;44(1):82–90. doi: 10.1136/hrt.44.1.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ryan M., Lown B., Horn H. Comparison of ventricular ectopic activity during 24-hour monitoring and exercise testing in patients with coronary heart disease. N Engl J Med. 1975 Jan 30;292(5):224–229. doi: 10.1056/NEJM197501302920502. [DOI] [PubMed] [Google Scholar]
  15. Savage D. D., Seides S. F., Maron B. J., Myers D. J., Epstein S. E. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation. 1979 May;59(5):866–875. doi: 10.1161/01.cir.59.5.866. [DOI] [PubMed] [Google Scholar]
  16. Singh B. N., Vaughan Williams E. M. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970 Aug;39(4):657–667. doi: 10.1111/j.1476-5381.1970.tb09891.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Stewart S., Mason D. T., Braunwald E. Impaired rate of left ventricular filling in idiopathic hypertrophic subaortic stenosis and valvular aortic stenosis. Circulation. 1968 Jan;37(1):8–14. doi: 10.1161/01.cir.37.1.8. [DOI] [PubMed] [Google Scholar]
  18. Ward D. E., Camm A. J., Spurrell R. A. Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. Br Heart J. 1980 Jul;44(1):91–95. doi: 10.1136/hrt.44.1.91. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES